Neutrophil (PMN) migration across intestinal epithelial barriers, such as occurs in many disease states, results in modifications in epithelial barrier. Here, we investigated the impact of lipoxin A4 (LXA4), an eicosanoid with counterregulatory inflammatory roles, on PMN migration across cultured monolayers of the human intestinal epithelial cell line T84. Transepithelial migration of PMN was assessed in the apical-to-basolateral direction and in the basolateral-to-apical direction. In the apical-to-basolateral direction, preexposure of PMN to LXA4 (10 nM, 15 min) stimulated an 87±5% increase in transepithelial migration of PMN as determined by a PMN myeloperoxidase assay. The LXA4-elicited effect on transmigration was present throughout the 2-h assay period and was not secondary to LXA4 effects on epithelial monolayer integrity as judged by measurement of transepithelial resistance. PMN migration in the basolateral-to-apical direction was modulated by LXA4 with a comparable time-and concentration-dependence to that in the apical-to-basolateral direction. However, qualitative differences in how LXA4 modulates transmigration in the two opposing directions were observed. In the basolateral-to-apical direction, preexposure of PMN to LXA4 (10 nM, 15 min) diminished PMN transepithelial migration by 33±4%. Structure-function studies revealed that LXA4 and 1 1-trans-LXA4 (50% of LXA4 effect), but not LXB4, inhibited basolateral-toapical PMN transmigration. The action of LXA4 was not sensitive to inhibitors of cyclooxygenase or specific leukotriene biosynthesis, but was sensitive to staurosporine, a protein kinase C inhibitor. These results suggest that migration of PMN across epithelia in the physiological direction may be qualitatively different following PMN exposure to eicosanoids. We propose that such retention of PMN at this specific anatomic location may serve an important role in mucosal defense. (J. Clin. Invest. 1993. 92:75-82.)
Introduction
PMN migration across intestinal epithelia is the hallmark of active intestinal inflammation and occurs in such disease states as ulcerative colitis, Crohn's disease and infectious enterocolitis ( 1, 2) . Transepithelial migration of PMN is particularly evident in the intestinal crypt and eventuates in crypt abscess formation, a characteristic of severe inflammatory disease ( 1, 2) . In patients with inflammatory bowel disease, the degree of PMN transepithelial migration, assessed quantitatively, has been shown to correlate with patients symptoms, as well as with the degree of intestinal epithelial barrier dysfunction (3) . Studies of human mucosa in such diseases suggest that PMN transepithelial migration predates focal breakdown of the epithelial surface ( 1, 2) , and that defective epithelial barrier function also predates structural discontinuities in the mucosa (4) .
An early and crucial step in the acute inflammatory response is attachment of neutrophils (PMN) to endothelial surfaces and subsequent emigration from the vasculature ( 1, 2) . However, during inflammatory episodes in organs lined by columnar epithelia, subsequent PMN migration across the epithelial surface occurs ( 1, 2) . While substantial progress has been made in the understanding of PMN-endothelial interactions (5) (6) (7) (8) (9) , relatively limited information is available concerning PMN-epithelial interactions (10) (11) (12) (13) (14) (15) . We have previously modelled the event of PMN transepithelial migration using human PMN and cultured, human-derived, intestinal epithelial monolayers derived from the cell line T84 (reviewed in reference 16). Such monolayers are composed of columnar epithelial cells with features similar to those of natural crypt epithelia ( 17, 18) , the site at which the bulk of PMN transepithelial migration occurs in a variety of active inflammatory intestinal diseases ( 1, 2) .
Previous studies using this epithelium as a model for examination of PMN-intestinal epithelial interactions indicate that PMN transmigration elicits a reversible decrease in transepithelial resistance caused by impalement of intercellular tight junctions ( 1) , and requires the PMN ,B2-integrin CDl lb/CD 18 (14, 15) . While we have shown that PMN transmigration is quantitatively more substantial in the physiological (basolateral-to-apical) direction ( 14) , qualitative differences in transepithelial migration, relating to the direction of transmigration, have generally not been observed ( 1 1, 12, 14) (with the exception of IFN-y-modulated PMN transepithelial migration [ 19] ).
Lipoxins are lipoxygenase-derived, biologically active eicosanoids produced by PMN, platelets, eosinophils, and macrophages (20, 21 ) . These compounds have been shown to elicit selective counterregulatory responses in human PMN in vitro, including the inhibition of leukotriene B4 (LTB4) and FMLPstimulated chemotactic responses (22, 23) , blocking of Ca2+ mobilization (24) , and inhibition of LTD4-induced adhesion to mesangial cells (25) . In vivo, lipoxins are potent inflammatory mediators which act to inhibit leukocyte migration (26) , decrease LTD4-induced vasoconstriction (27) and modulate LTD4-induced airway obstruction (28 ( 16) . Transepithelial resistance to passive ion flow was measured as previously described (14) (15) (16) . Inverted monolayers, used to study transmigration ofPMN in the basolateral-to-apical direction, were constructed as described before ( 14, 16) . Transmigration assay. The PMN transepithelial migration assay has been previously detailed (1 1, 12, 14, 15) . Briefly, human PMN were isolated from normal human volunteers and suspended in modified HBSS (without Ca2" and Mg2", with 10 mM Hepes, pH 7.4, Sigma Immunochemicals, St. Louis, MO) at a concentration of 5 X 107/ml. Before addition of PMN, T84 monolayers were extensively rinsed in HBSS to remove residual serum components. Transmigration assays were performed by the addition of PMN (40 ,l) to HBSS ( 160 ul) in the upper chambers after chemoattractant (1 MuM FMLP in HBSS) was added to the opposing (lower) chambers. Unless otherwise indicated, PMN were not washed free of LXA4 before addition to monolayers, and therefore, a fivefold dilution of lipoxin was present during the transmigration assay. For apical-to-basolateral transmigration experiments, PMN (2 X 106) were added at time 0. We have previously shown that transmigration in the basolateral-to-apical direction, while qualitatively similar, is substantially more efficient than in the apical-to-basolateral direction ( 14) . Therefore, fivefold fewer PMN (4 x 10) were added when transmigration proceeded in the basolateral-to-apical direction so that baseline transmigration signals be approximately equivalent in both directions (14) . Transmigration was allowed to proceed for 120 min, unless otherwise noted. All PMN Transmigration was quantitated by assaying for the PMN azurophilic granule marker myeloperoxidase (MPO) as described previously ( 14) . After each transmigration assay, nonadherent PMN were extensively washed from the surface ofthe monolayer, and PMN cell equivalents (PMN CE), estimated from a standard curve, were assessed as the number of PMNs associated with the monolayer, the number that had completely traversed the monolayer (i.e., across the monolayer into the reservoir bath), as well as the total number oftransmigrating PMN (the sum of monolayer and reservoir-associated PMN).
Data presentation. Individual experiments were performed using large numbers of uniform groups of monolayers and PMN from individual blood donors on individual days. PMN ( 11, 14) . To determine whether LXA4 exposure to T&4 intestinal epithelial cells influenced subsequent PMN transmigration, epithelial cell monolayers were incubated with LXA4 at a concentration 10 nM for 15 min at 37°C (conditions which elicit significant effects when PMN's are preexposed to LXA4, see below), with and without removal of LXA4 from monolayers, followed by addition of untreated PMNs under chemotactic conditions. In these experiments, PMN transmigration across T84 monolayers exposed to LXA4 did not differ from vehicle control ( 14.8±1.4 vs 15.7±1.8 X 104 PMN CE/ml for control and LXA4-exposed monolayers, n = 6 each, NS). Removal of LXA4 from monolayers by washing three times with HBSS before addition of PMN had no apparent effect on the total number of transmigrating PMN ( 14.3±1.1 X 104 PMN CE/ml, n = 6, NS compared to either control or LXA4-exposed monolayers).
In Preexposure of PMN to LXA4 enhances FMLP-induced PMN transmigration in the apical-to-basolateral direction. To determine if PMN exposure to LXA4 alters subsequent FMLPinduced transmigration, PMN were incubated with 10 nM LXA4 for 15 min, then added directly to the apical surface of T84 epithelial monolayers, and subsequently assessed for their ability to traverse T84 epithelial monolayers using a myeloperoxidase assay ( 14) . PMN preexposure to LXA4 resulted in significantly increased PMN transepithelial migration in the apical-to-basolateral direction ( Fig. 1 ). Increased PMN migration was evident in both monolayer-associated PMN numbers (2.98±0.57 vs 6.93±1.77 X 104 PMN CE/monolayer for vehicle control and LXA4-exposed PMN, respectively, P < .001 ), as well as the number of PMN that completely traversed the epithelial monolayer (6.61±0.50 vs 11.02±2.91 x 104 PMN CE/ml for vehicle control and LXA4-exposed, respectively, P < 0.01 ), resulting in a nearly twofold increase in the total number oftransmigrating PMN (9.58±1.05 x 104 PMN CE/ml for vehicle control and 17.95±2.15 X 104 PMN CE/ml for LXA4 preexposed PMN, P < 0.01 ). As reported previously ( 14) , examination of 1 ,m T84 epithelial monolayer sections revealed that PMNs are only rarely associated with the apical epithelial surface and the majority of monolayer-associated PMN are found subjunctionally, indicative of transmigration. Therefore, monolayer-associated PMN in this apical-to-basolateral assay are considered transmigrated across the tight junction, the rate-limiting barrier in PMN transepithelial migration ( 14) .
To further characterize this transmigratory event, PMNs were preexposed to LXA4 (10 nM) for various periods of time and subsequently assessed for their ability to transmigrate across T84 epithelial monolayers in the apical-to-basolateral direction (Fig. 2) . Results in Fig. 2 A show that preexposure of PMNs to LXA4 resulted in increased total PMN transmigration after a LXA4 preexposure period of 5-30 min. (compared to vehicle controls, for PMNs preexposed to 10 nM LXA4, transmigration increased by 50, 68, and 51% at 5, 15, and 30 min exposure times, respectively, all P < 0.025). Transmigration had returned to vehicle control values by 45 and 60 min of PMN preexposure to LXA4. Preexposure of PMN to LXA4 was found to be a necessary prerequisite for LXA4 action on stimulating PMN transmigration. Indeed, exposure of PMNs to 10 nM LXA4 immediately before their addition to epithelial monolayers (i.e., 0 min preexposure) resulted in no effect on subsequent FMLP-induced PMN migration ( The concentration dependence of LXA4 preexposure to PMN and subsequent PMN transepithelial migration in the apical-to-basolateral direction is shown in Fig. 2 PMN CE /ml for control and LXA4 exposure followed by washout, respectively, n = 6 each, NS). In the presence of LXA4, a total of 18.6±1.0 X 104 PMN CE/ml migrated (n = 6, P < 0.025 compared to control and washout control), suggesting that LXA4-induced enhancement of PMN migration in the apical-to-basolateral direction requires the presence of LXA4. Finally, we determined whether PMN-conditioned LXA4 and epithelial-conditioned LXA4 maintained its ability to enhance PMN transmigration in the apical-to-basolateral direction. Samples of LXA4 (10 nM) were incubated with either PMN or T84 epithelial cells for 15 or 45 min. Supernatants were harvested and subsequently exposed to PMN for 15 min and added to the apical surface of T84 monolayers under transmigratory conditions (1,uM FMLP transepithelial gradient) for 2 h at 37°C. Compared to PMN preexposed to HBSS (11.3±2.2 X 104 total PMN CE/ml), PMN preexposed to PMN-conditioned LXA4 (15 min) resulted in a total PMN migration 18.0±2.1 X 104 PMN CE/ml (n = 3, P < 0.05 compared to control). PMN preexposed to epithelial-conditioned LXA4 (15 min) resulted in a total PMN migration 16.8±3.3 X 104 PMN CE/ml (n = 3, P < 0.05 compared to control). Supernatants from PMN-conditioned LXA4 (45 min) were not effective in enhancing PMN transmigration in the apical-to-basolateral direction (12.36±3.1 X 104 total PMN CE/ml compared to HBSS control of 14.3±3.2 X 104 total PMN CE/ml, n = 3, P = NS). These results suggest that enhancement ofPMN migration in the apical-to-basolateral direction involves a step that is subsequent to PMN preincubation with LXA4.
PMNpreexposure to LXA4 decreases FMLP-induced PMN transmigration in the basolateral-to-apical direction. We have recently reported that quantitative as well as qualitative differences can exist in PMN transepithelial migration depending on the direction of migration (19) . To investigate the effect of LXA4 on the polarity of transmigration, we prepared inverted monolayers (which permit basolateral-to-apically directed transmigration) to assess whether PMN preexposure to LXA4 exhibited similar effects as shown above on subsequent PMN transmigration. Results in Fig. 4 show that preexposure of PMN to LXA4 (10 nM) for 15 min markedly decreased PMN transmigration in the basolateral-to-apical direction. Unlike the results found in the apical-to-basolateral direction, transmigration of PMNs in this physiologically relevant direction was significantly decreased compared to vehicle controls (28.02±3.08 vs 18.77±1.48 X 104 PMN/ml for control and PMNs preexposed to 10 nM LXA4 for 15 min, respectively, P < 0.01, Fig. 4) . Transmigration in the basolateral-to-apical direction resulted in no significant difference in the number of monolayer-associated PMNs after preexposure to LXA4 (Fig.  4, 2 .01±0.20 vs 2.00±0.31 for control and PMN exposed to LXA4, respectively, P = NS). This polarized action of LXA4 was confirmed by performing parallel apical-to-basolateral and 10 and 1 nM LXA4, respectively, both P < 0.025). Again, this diminished transmigratory response in the basolateral-to-apical direction was associated with reservoir-associated PMN only, with no apparent effect on the number of monolayer-associated PMN.
We also determined whether PMN-conditioned LXA4 or epithelial-conditioned LXA4 were effective in decreasing PMN transmigration in the basolateral-to-apical direction. Similar to our results in the apical-to-basolateral direction (see above), PMN preexposed to either PMN-conditioned LXA4 (8.07±1.63 vs buffer control 13.18±1.91 X 104 PMN/ml, n = 4, P < 0.025) or epithelial-conditioned LXA4 (9.01±1.76 compared to buffer control of 14.23±2.06 X 104 PMN/ml, n = 4, P < 0.04) maintained activity that decreased PMN transepithelial migration in the basolateral-to-apical direction.
Preexposure of PMN to structurally related lipoxins. To investigate the specificity of LXA4 causing decreased transmigration in the physiological direction, we also examined the effects of PMN exposure LXB4 and 1 1-trans-LXA4 (Fig. 6 ). PMN's were preincubated with these compounds using conditions as described above ( 10 nM, 15 Vehicle Control inhibited migration by 28±4% (P < 0.01). These observations suggest structural specificity for LXA4.
Effect ofinhibitors on LXA4-elicited enhancement ofPMN transepithelial migration in the apical-to-basolateral direction. To determine whether LXA4-induced modulation of PMN transmigration could be pharmacologically altered, a series of experiments were done in which PMN were exposed to specific inhibitors, washed free of inhibitor and subsequently assayed for the LXA4 effect on PMN transepithelial migration in the apical-to-basolateral direction.
Preexposure of PMN to indomethacin (50 ,M, 15 min, 37°C), a cyclooxygenase inhibitor (30) , did not effect baseline PMN transmigration in the presence of a transepithelial gradient of FMLP ( 109±13% vehicle control, n = 6, P = NS compared to untreated control). Likewise, preexposure of PMN to indomethacin followed by exposure to LXA4 (10 nM) did not alter the LXA4-elicted increase in FMLP-driven PMN transmigration in the apical-to-basolateral direction (61 ± 11% increase vs 54±7% increase over control for LXA4-treated PMN with and without indomethacin, respectively, P = NS). In addition, PMN pretreatment with the compound MK886 (10 ng/ml), a specific inhibitor of leukotriene generation ( 31 ) , did not alter baseline FMLP-driven PMN transmigration and did not effect the LXA4-elicited increase in PMN transepithelial migration (data not shown).
Staurosporine, a potent inhibitor of protein kinase C (PKC) (32) , was assessed for its ability to inhibit the LXA4 effect. Interestingly, staurosporine alone (10 nM final concentration) was found to inhibit PMN transepithelial migration (93±5% inhibition vs vehicle control, n = 3, P < 0.001 ). These data were also confirmed using the PKC inhibitor H7 (33) (100 ,M final concentration, 91±4% inhibition compared to vehicle control, n = 3, P < 0.001 ). Likewise, the LXA4-elicited (10 nM) increment in transmigration was sensitive to staurosporine (89±7% inhibition compared to vehicle control, n = 3, P < 0.001). Preexposure of PMN to pertussis toxin (34) (2 ,ug/ml) also inhibited baseline FMLP-driven transmigration (91±8% inhibition compared to vehicle control, n = 6, P < 0.001 ). The LXA4-elicited (10 nM) increase in PMN transmigration (46±3% increase compared to control, P < 0.01) was also sensitive to PMN preexposure to pertussis toxin (87±4% inhibition of control, n = 6, P < 0.001 ).
We next assessed the possibility ofdifferential sensitivity to staurosporine for baseline and LXA4-stimulated increases in FMLP-driven PMN transmigration. Staurosporine inhibited baseline PMN transepithelial migration in a dose-dependent manner (94±4%, 96±9%, 67±11%, 54+8%, 35±11%, and I 1 ±6% inhibition compared to vehicle controls for concentrations of 100, 10, 1, 0.1, 0.01, and 0.001 nM staurosporine, respectively, P < 0.01 by ANOVA). From this dose response, we selected a concentration that was approximately half-maximal in inhibiting PMN transmigration (0.1 nM, see above). PMN were then preexposed to staurosporine (0.1 nM, 15 min, 37°C), washed free of inhibitor, and subsequently assessed for the LXA4 effect on PMN transepithelial migration. Here, the LXA4-elicited increase in transepithelial migration of PMN was observed to be sensitive to PKC inhibition, since the relative inhibition by staurosporine was equivalent with and without LXA4 (54±6% and 49±7% decrease in total PMN transmigration for staurosporine-treated PMN in the presence and absence ofLXA4, respectively, P = NS; both decreased compared to staurosporine-untreated controls, n = 6, P < 0.025). These results indicate that LXA4-elicited increases in PMN transmigration in the apical-to-basolateral direction are not sensitive to inhibition ofthe cyclooxygenase pathway or the specific inhibition of leukotriene generation, but is sensitive to inhibitors of PKC.
Discussion
During inflammatory processes, PMN are recruited from the blood by signals derived at inflammatory sites. At sites ofacute inflammation, PMN function may be regulated by a variety of inflammatory signals, including both protein-and lipid-derived signals. PMN function at organ-specific sites, including the intestine, is thought to contribute to epithelial dysfunction during disease. Here we report for the first time that the arachidonic acid-derived eicosanoid LXA4 modulates PMN migration across a model human intestinal epithelium. In addition, we report that LXA4 exerts an effect on transmigration in a polarized fashion.
LXA4 enhances PMN transepithelial migration in the apical-to-basolateral direction. For technical reasons, previous studies of PMN transepithelial migration have focused on "nonphysiologically" oriented monolayers, in which leukocyte migration is in the apical-to-basolateral direction ( 11, 13, 14, 19, 35 ) . PMNs preexposed to LXA4and driven to transmigrate across epithelial monolayers oriented nonphysiologically resulted in enhanced PMN migration (Figs. 1 and 2 ). The action of LXA4 was found to be specific for PMN but not epithelial cells, since enhanced PMN migration in this direction was dose-and time-dependent, and no measurable effects on PMN transepithelial migration were observed when epithelial monolayers were preexposed to LXA4 under conditions that promoted enhanced PMN migration. These results are consistent with previous studies which report that LXA4, in similar concentrations used here, was capable of activating PMN in vitro (36) . In our model system, LXA4 enhanced PMN transmigration in a manner independent to that of FMLP, since in all conditions PMN migration was driven toward a gradient of FMLP, suggesting that the proportion of PMN migration exceeding that of FMLP controls is dependent on a LXA4-mediated event. Moreover, these results suggest that the action of LXA4 may be synergistic with FMLP, since LXA4by itselfdoes not promote PMN migration in the absence of FMLP (see Results).
We have also found that preexposure of PMN to LXA4 modulates migration of PMN in a polarized manner. That is, an opposite effect was observed depending on the direction of PMN migration. The observed effect of LXA4 inhibition of PMN transmigration in the physiologically oriented (basolateral-to-apical) direction was dependent on concentration, as well as the duration of preexposure (Figs. 4 and 5) . These effects were found to be selective for LXA4, since no effect was observed with the positional isomer LXB4 (Fig. 6 ). As described for leukocyte movement across endothelia (38) ( 14) . In addition, PMN transepithelial migration can be regulated by exposure of T84 epithelial monolayers to the lymphokine IFN-y ( 19) . In light of the polarized nature of this epithelium ( 17, 18, 37) , it would not be surprising that the sequence by which PMN encounters epithelial ligands directly regulates PMN transmigration. Moreover, PMN migration across endothelia requires a sequential series of activation and deactivation steps on the PMN surface, of which lipid-derived activating factors may play an important role (reviewed in reference 38). Whether LXA4 could act as a lipid-derived factor for expression of a crucial ligand in the regulation of PMN transmigration across epithelia is not known. Evidence to support this hypothesis is provided by a recent study characterizing lipoxin binding sites on human PMN (39) . With a reported Kd of0.5 nM and -1,800 binding sites per cell, the range of LXA4 concentrations used in the present study (0.01-10 nM) should provide maximal activation of subsequent signal transduction steps, most of which remain to be elucidated, but appears to involve a G protein-associated activation step (39) and possibly a signaling step through PKC as determined by inhibition using staurosporine (see Results).
Recent in vivo studies have shown that LXA4 is an important inflammatory mediator at several distict anatomic sites, including the lung (28), kidney (40) , blood vessel (41) , and hamster cheek pouch (26) . The data reported here suggest that LXA4-elicited alterations exert effects at the level of PMN and subsequently modulate PMN-epithelial interactions. Previous studies have shown that production of lipoxygenase products of arachidonic acid correlates with intestinal inflammation. Specifically, an enhanced conversion of arachidonate to 5-, 12-and 1 5-hydroxy-eicosatetraenoic acid (HETE) has been shown in ulcerative colitis homogenates (42) as well as increased biosynthesis of LTB4 in Crohn's disease (43) . The present results suggest that lipoxins, and specifically by their action on PMN, may play a role in intestinal disease.
